Citigroup Inc. Sells 13,427 Shares of Arcellx, Inc. $ACLX

Citigroup Inc. cut its position in Arcellx, Inc. (NASDAQ:ACLX) by 12.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,845 shares of the company’s stock after selling 13,427 shares during the quarter. Citigroup Inc. owned about 0.16% of Arcellx worth $7,623,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. CWM LLC raised its position in shares of Arcellx by 267.0% in the third quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after buying an additional 251 shares in the last quarter. State of Wyoming bought a new position in Arcellx in the 2nd quarter worth about $28,000. PNC Financial Services Group Inc. increased its stake in Arcellx by 183.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock worth $49,000 after acquiring an additional 486 shares during the last quarter. Abich Financial Wealth Management LLC purchased a new stake in shares of Arcellx in the 3rd quarter valued at about $62,000. Finally, Principal Financial Group Inc. bought a new stake in shares of Arcellx during the 3rd quarter valued at about $215,000. 96.03% of the stock is currently owned by hedge funds and other institutional investors.

Arcellx News Summary

Here are the key news stories impacting Arcellx this week:

• Neutral Sentiment: Reported short-interest data shows zero shares and a 0.0 days-to-cover figure for late February; this looks like a data or reporting anomaly rather than a meaningful change in market positioning — monitor for corrected filings or confirmations from exchanges.
• Neutral Sentiment: HC Wainwright published an FY2030 earnings forecast for Arcellx; long-range model updates can influence valuation assumptions but are less likely to move the stock immediately than near-term operational news. FY2030 Earnings Forecast for Arcellx Issued By HC Wainwright
• Neutral Sentiment: Market commentary pieces (example: “Is It Too Late To Consider Arcellx…”) are evaluating the recent run-up and valuation; these are background reads that may sway retail interest but do not constitute new company fundamentals. Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge?
• Negative Sentiment: Insider selling: Director Rami Elghandour sold 89,916 shares at ~$113.92 (≈$10.24M), cutting his stake by ~24.6%. Large insider sales at current levels can weigh on sentiment, especially after a recent price run. SEC Filing
• Negative Sentiment: Quarterly results: ACLX reported EPS of ($1.01), matching consensus, but revenue was $1.65M vs. expectations of $13.4M — a sizable revenue shortfall that highlights execution or timing risk and likely increases near-term volatility and downside pressure.
• Negative Sentiment: Analyst actions: UBS downgraded the stock, and both Robert W. Baird and Canaccord Genuity moved ACLX to “Hold” — multiple downward analyst moves reduce buy-side momentum and can trigger short-term selling. UBS downgrades Arcellx (ACLX) Cut to Hold at Robert W. Baird Cut to Hold at Canaccord Genuity Group

Insider Buying and Selling

In other news, insider Rami Elghandour sold 89,916 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $113.92, for a total value of $10,243,230.72. Following the transaction, the insider owned 276,051 shares in the company, valued at approximately $31,447,729.92. This trade represents a 24.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Heery sold 7,437 shares of Arcellx stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $65.51, for a total transaction of $487,197.87. Following the completion of the transaction, the insider directly owned 29,631 shares in the company, valued at approximately $1,941,126.81. The trade was a 20.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 109,366 shares of company stock worth $11,526,708 over the last ninety days. Insiders own 8.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ACLX. Needham & Company LLC downgraded shares of Arcellx from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Wells Fargo & Company cut shares of Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 price objective on the stock. in a research report on Monday, February 23rd. William Blair lowered shares of Arcellx from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 23rd. Wolfe Research started coverage on Arcellx in a research note on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Finally, UBS Group lowered Arcellx from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $100.00 to $115.00 in a research note on Tuesday, February 24th. One research analyst has rated the stock with a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $111.87.

Arcellx Trading Down 0.1%

Shares of NASDAQ:ACLX opened at $113.79 on Monday. The stock has a market capitalization of $6.65 billion, a P/E ratio of -28.95 and a beta of 0.22. The stock’s 50-day moving average price is $71.81 and its 200-day moving average price is $76.28. Arcellx, Inc. has a 12-month low of $47.86 and a 12-month high of $114.26.

Arcellx Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.